Monoclonal antibodies

United States Pancreatic Cancer Market Analysis 2020-2025

Tuesday, September 22, 2020 - 9:30pm

This report provides comprehensive insights into Pancreatic Cancer pipeline products, Pancreatic Cancer epidemiology, Pancreatic Cancer market valuations and forecast, Pancreatic Cancer drugs sales and competitive landscape in the US.

Key Points: 
  • This report provides comprehensive insights into Pancreatic Cancer pipeline products, Pancreatic Cancer epidemiology, Pancreatic Cancer market valuations and forecast, Pancreatic Cancer drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Pancreatic Cancer treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Pancreatic Cancer pipeline: Find out the products in clinical trials for the treatment of Pancreatic Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Pancreatic Cancer drugs: Identify key products marketed and prescribed for Pancreatic Cancer in the US, including trade name, molecule name, and company
    Pancreatic Cancer market valuations: Find out the market size for Pancreatic Cancer drugs in 2019 in the US.
  • Find out how the market advanced from 2016 and forecast to 2025
    Pancreatic Cancer drugs market share: Find out the market shares for key Pancreatic Cancer drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Pancreatic Cancer products

Can-Fite to Participate in Two BioPharma Partnering Conferences

Tuesday, September 22, 2020 - 12:00pm

Interim top-line results are expected before the end of 2020 in two Phase III studies of Piclidenoson in rheumatoid arthritis and psoriasis.

Key Points: 
  • Interim top-line results are expected before the end of 2020 in two Phase III studies of Piclidenoson in rheumatoid arthritis and psoriasis.
  • Can-Fite has received approximately $18 million in upfront and milestone payments to date through licensing and distribution deals for its drug candidates.
  • The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis.
  • Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)

Tuesday, September 22, 2020 - 11:59am

Together with our partners at Bristol Myers Squibb, we are committed to continue working with the FDA to deliver this promising therapy to patients in an expeditious manner.

Key Points: 
  • Together with our partners at Bristol Myers Squibb, we are committed to continue working with the FDA to deliver this promising therapy to patients in an expeditious manner.
  • Bristol Myers Squibb plans regulatory submissions for ide-cel in additional markets outside the U.S. and EU.
  • Ide-cel is being developed as part of a Co-Development, Co-Promotion and Profit Share Agreement between Bristol Myers Squibb and bluebird bio.
  • Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): initial KarMMa results.

Anokion Announces Expansion of Exclusive Collaboration with Bristol Myers Squibb to Develop Novel Treatments for Autoimmune Diseases

Tuesday, September 22, 2020 - 11:30am

We are excited to expand our relationship with Bristol Myers Squibb, which underscores the substantial therapeutic opportunity we believe our programs hold for people with autoimmune diseases who lack disease-modifying treatments today, said John Hohneker, M.D., president and chief executive officer of Anokion.

Key Points: 
  • We are excited to expand our relationship with Bristol Myers Squibb, which underscores the substantial therapeutic opportunity we believe our programs hold for people with autoimmune diseases who lack disease-modifying treatments today, said John Hohneker, M.D., president and chief executive officer of Anokion.
  • Bristol Myers Squibb is an industry leader with significant capabilities across all phases of drug development.
  • Anokion is responsible for preclinical activities and Phase 1 clinical development of partnered programs, and Bristol Myers Squibb will fund subsequent trials and commercial activities at clinical proof-of-concept.
  • We look forward to further collaborating with Anokion to bring potential new treatments to patients with autoimmune diseases.

Europe Wet Age-Related Macular Degeneration Market and Competitive Landscape Report 2020: Pipeline, Epidemiology, Market Valuations, Drug Sales, Market Forecast, Drug Forecasts, & Market Shares - ResearchAndMarkets.com

Tuesday, September 22, 2020 - 9:29am

The "Europe Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • Europe Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2020, provides comprehensive insights into the Wet Age-Related Macular Degeneration pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Wet Age-Related Macular Degeneration market size and drug sales.
  • Wet Age-Related Macular Degeneration pipeline: Find out drugs in clinical trials for the treatment of Wet Age-Related Macular Degeneration by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Wet Age-Related Macular Degeneration epidemiology: Find out the number of patients diagnosed (prevalence) with Wet Age-Related Macular Degeneration by countries
    Wet Age-Related Macular Degeneration drugs: Identify key drugs marketed and prescribed for Wet Age-Related Macular Degeneration in the US, including trade name, molecule name, and company
    Wet Age-Related Macular Degeneration drugs sales: Find out the sales value for Wet Age-Related Macular Degeneration drugs by countries
    Wet Age-Related Macular Degeneration market valuations: Find out the market size for Wet Age-Related Macular Degeneration drugs in 2019 by countries.

Bristol Myers Squibb Completes Acquisition of Forbius

Monday, September 21, 2020 - 9:16pm

Davis Polk & Wardwell LLP and Osler, Hoskin & Harcourt LLP served as legal advisors to Bristol Myers Squibb.

Key Points: 
  • Davis Polk & Wardwell LLP and Osler, Hoskin & Harcourt LLP served as legal advisors to Bristol Myers Squibb.
  • Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .
  • These risks, assumptions, uncertainties and other factors include, among others, any delay or inability of Bristol Myers Squibb to realize the expected benefits of the transaction.

Opdivo (nivolumab) Demonstrated Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to Placebo in the Adjuvant Setting

Monday, September 21, 2020 - 5:31pm

The current standard of care for patients with esophageal or GEJ cancer following neoadjuvant CRT and tumor resection is surveillance.

Key Points: 
  • The current standard of care for patients with esophageal or GEJ cancer following neoadjuvant CRT and tumor resection is surveillance.
  • Adjuvant treatment with nivolumab in the CheckMate -577 trial doubled patients time without disease recurrence, representing the first adjuvant treatment advancement for these patients with esophageal or gastroesophageal junction cancer.
  • In MSI-H/dMMR mCRC patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg, immune-mediated pneumonitis occurred in 1.7% (2/119) of patients.
  • In MSI-H/dMMR mCRC patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg, immune-mediated colitis occurred in 7% (8/119) of patients.

Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020

Monday, September 21, 2020 - 3:20pm

Genmab A/S (Nasdaq: GMAB) and Seattle Genetics, Inc. (Nasdaq: SGEN) today presented data from the innovaTV 204 pivotal phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent and/or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Key Points: 
  • Genmab A/S (Nasdaq: GMAB) and Seattle Genetics, Inc. (Nasdaq: SGEN) today presented data from the innovaTV 204 pivotal phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent and/or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
  • Tisotumab vedotin has demonstrated meaningful clinical activity in patients with recurrent and/or metastatic cervical cancer for whom there is a high unmet need for new therapies, said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics.
  • Data presented at ESMO include the primary endpoint of confirmed ORR as assessed by independent central review in 101 patients treated with tisotumab vedotin in the trial.
  • For more information about the phase 2 innovaTV 204 clinical trial and other clinical trials with tisotumab vedotin, please visit www.clinicaltrials.gov.

Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020

Monday, September 21, 2020 - 3:20pm

Seattle Genetics, Inc. (Nasdaq:SGEN) and Genmab A/S (Nasdaq: GMAB) today presented data from the innovaTV 204 pivotal phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent and/or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Key Points: 
  • Seattle Genetics, Inc. (Nasdaq:SGEN) and Genmab A/S (Nasdaq: GMAB) today presented data from the innovaTV 204 pivotal phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent and/or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
  • We are encouraged by the innovaTV 204 trial results, which suggests that tisotumab vedotin as a monotherapy could potentially become an important option for women with metastatic and or recurrent cervical cancer, said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
  • Data presented at ESMO include the primary endpoint of confirmed ORR as assessed by independent central review in 101 patients treated with tisotumab vedotin in the trial.
  • For more information about the phase 2 innovaTV 204 clinical trial and other clinical trials with tisotumab vedotin, please visit www.clinicaltrials.gov.

Tiziana Life Sciences plc: Publication of Research Note

Monday, September 21, 2020 - 2:51pm

LONDON and NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), is pleased to note the publication of a new analyst research note from H C Wainwright & Co which is available on the Companys website at https://ir.tizianalifesciences.com/static-files/0bae55ef-6589-43f2-a4bd-...

Key Points: 
  • LONDON and NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), is pleased to note the publication of a new analyst research note from H C Wainwright & Co which is available on the Companys website at https://ir.tizianalifesciences.com/static-files/0bae55ef-6589-43f2-a4bd-...
    Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases.
  • In addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohns Disease and nasally administered foralumab for progressive multiple sclerosis.
  • Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world.
  • The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.